
"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
Cancer that has spread elsewhere in the body is called advanced cancer. Docetaxel chemotherapy is a usual treatment for advanced prostate cancer if hormone therapy has stopped working. Treatment might also include a called prednisolone.
In this trial, doctors looked at adding a type of targeted drug called custirsen (OGX-011) to improve treatment.
Some cancer cells produce a lot of a protein called clusterin. This may help them to protect themselves from cancer drugs and stop the drugs working as well as they could. Custerin reduces the level of clusterin. Researchers hoped that by lowering the levels of clustirsen, the cancer drugs would work better.
In this trial, some men had docetaxel, prednisolone and custirsen. And some had docetaxel and prednisolone.
The aim of the trial was to see if adding custirsen to docetaxel and prednisolone improved treatment for advanced prostate cancer.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann de Bono
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Oncogenex
Teva Pharmaceutical Industries Ltd
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”